The results could reinforce Eli Lilly and Novo Nordisk's dominance in the booming market for weight loss and diabetes drugs.
In this article
Shares of Viking Therapeutics
fell more than 30% in premarket trading Tuesday after the company released mid-stage trial data on its obesity pill that disappointed investors.
The results could be a blow to Viking, which was once seen as a hot M&A target as pharmaceutical companies scramble to join the booming market for obesity and diabetes drugs. It could reinforce Eli Lilly
and Novo Nordisk
The early data is a boost to the Danish drugmaker's hopes of winning back more market share from Eli Lilly this year in the…
Novo Nordisk stock fell as much as 10% Monday after it said its next-generation weight loss drug didn't meet its primary target.
The company said the weight loss and diabetes treatment drug failed to show any significant reduction in the progression of…
Danish drugmaker jumps by about £9bn as trial shows ‘significant weight loss’ with tablet version of Wegovy
Shares of Novo Nordisk plunged after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer's…
Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions and…
